Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
INLB Stock Summary
In the News
Item 9 Labs Corp. (INLB) CEO Andrew Bowden on Q3 2022 Results - Earnings Call Transcript
Item 9 Labs Corp. (OTCQX:INLB) Q3 2022 Earnings Conference Call August 16, 2022 8:30 AM ET Company Participants Jason Assad - Investor Relations Andrew Bowden - Chief Executive Officer Bobby Mikkelsen - Chief Financial Officer Jason Assad [Abrupt Start] Joining me on today's call is our Chief Executive Officer, Andrew Bowden and our Chief Financial Officer, Bobby Mikkelson. Shortly before this call, we filed our Form 10-Q, a copy of which is available on the company's website at item9labscorp.com.
Item 9 Labs Corp. (INLB) Reports Q3 Loss, Misses Revenue Estimates
Item 9 Labs Corp. (INLB) delivered earnings and revenue surprises of -100% and 29.56%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Item 9 Labs Corp. to Host Third Quarter Fiscal Year 2022 Earnings Call on August 16 at 8:30 a.m. ET
PHOENIX , Aug. 3, 2022 /PRNewswire/ -- Item 9 Labs Corp. (OTCQX: INLB) (the "Company")—a vertically integrated cannabis dispensary franchisor and operator that produces premium, award-winning products—announced today that it will host a conference call on Tuesday August 16, 2022, to share financial results for the third quarter of fiscal year 2022, which ended June 30, 2022. The 10Q will be filed on Monday, August 15, 2022.
Item 9 Labs Corp. (INLB) CEO Andrew Bowden on Q2 2022 Results - Earnings Call Transcript
Item 9 Labs Corp. (OTCQX:INLB) Q2 2022 Earnings Conference Call May 16, 2022 4:30 PM ET Company Participants Jason Assad - Investor Relations Andrew Bowden - Chief Executive Officer Bobby Mikkelsen - Chief Financial Officer Conference Call Participants Jason Assad Hello, this is Jason Assad, Investor Relations with Item 9 Labs. Good afternoon, and welcome to Item 9 Labs Fiscal Q2 2022 Results Conference Call for the three months ended March 31, 2022.
Item 9 Labs Corp. (INLB) Reports Q2 Loss, Lags Revenue Estimates
Item 9 Labs Corp. (INLB) delivered earnings and revenue surprises of -33.33% and 9.07%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Item 9 Labs Corp. to Present at Leading Investor Conferences in April
Vertically Integrated Cannabis Dispensary Franchisor and Operator to Share Recent Positive Momentum for Accelerated National Growth in 2022 PHOENIX , April 5, 2022 /PRNewswire/ -- Item 9 Labs Corp. (OTCQX: INLB) (the "Company") – a vertically integrated cannabis dispensary franchisor and operator that produces premium, award-winning products – announced today that the Company's executive team will be participating in multiple investor events in April. These events include: Noble Capital Markets' 18th Annual Small & Microcap Investor Conference (NobleCon18), Sequire's Cannabis & Psychedelic Virtual Conference and Benzinga's Spring Cannabis Capital Conference.
Unity Rd.'s Chief Franchise Officer to Present at International Franchise Association's 2022 Convention
PHOENIX, Feb. 21, 2022 /PRNewswire/ -- Unity Rd., the first true vertically integrated cannabis dispensary franchise from Item 9 Labs Corp. (OTCQX: INLB), continues to establish itself as a rising trailblazer in franchising.
Item 9 Labs Corp. (INLB) CEO Andrew Bowden on Q1 2022 Results - Earnings Call Transcript
Item 9 Labs Corp. (INLB) CEO Andrew Bowden on Q1 2022 Results - Earnings Call Transcript
Unity Rd.'s VP of Communications to Present at YoungConference
PHOENIX, Jan. 25, 2022 /PRNewswire/ -- Unity Rd., the cannabis dispensary franchise from Item 9 Labs Corp. (OTCQX: INLB), continues to solidify their position as industry trailblazers.
Item 9 Labs Corp.'s (INLB) CEO Andrew Bowden on Q4 2021 Results - Earnings Call Transcript
Item 9 Labs Corp.'s (INLB) CEO Andrew Bowden on Q4 2021 Results - Earnings Call Transcript
INLB Financial details
INLB Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2022-09-30
Metric | History | 2018-09-30 | 2019-09-30 | 2020-09-30 | 2021-09-30 | 2022-09-30 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 0.5 | 0.08 | 0.13 | 0.28 | 0.23 | |
Net income per share | -0.23 | -0.17 | -0.2 | -0.21 | -0.33 | |
Operating cash flow per share | -0.36 | -0.04 | -0.02 | -0.08 | -0.02 | |
Free cash flow per share | -0.55 | -0.14 | -0.03 | -0.11 | -0.08 | |
Cash per share | 0.06 | 0 | 0 | 0.02 | 0 | |
Book value per share | 0.96 | 0.12 | 0.13 | 1.11 | 0.66 | |
Tangible book value per share | 0.96 | 0.07 | -0.01 | 0.12 | -0.09 | |
Share holders equity per share | 0.96 | 0.12 | 0.13 | 1.11 | 0.66 | |
Interest debt per share | 0.01 | 0.13 | 0.24 | 0.34 | 0.36 | |
Market cap | 301.22K | 171.67M | 92.43M | 123.86M | 37.28M | |
Enterprise value | 151.95K | 176.42M | 100.23M | 143.34M | 65.04M | |
P/E ratio | -0.47 | -16.15 | -7.52 | -7.65 | -1.2 | |
Price to sales ratio | 0.22 | 34.79 | 11.38 | 5.65 | 1.71 | |
POCF ratio | -0.31 | -71.73 | -80.98 | -20.68 | -16.54 | |
PFCF ratio | -0.2 | -19.4 | -59.73 | -15.05 | -4.83 | |
P/B Ratio | 0.12 | 23.01 | 11.53 | 1.44 | 0.6 | |
PTB ratio | 0.12 | 23.01 | 11.53 | 1.44 | 0.6 | |
EV to sales | 0.11 | 35.76 | 12.34 | 6.53 | 2.99 | |
Enterprise value over EBITDA | -0.25 | -55.64 | -23.06 | -32.95 | -5.81 | |
EV to operating cash flow | -0.16 | -73.71 | -87.81 | -23.93 | -28.85 | |
EV to free cash flow | -0.1 | -19.93 | -64.77 | -17.41 | -8.43 | |
Earnings yield | -2.13 | -0.06 | -0.13 | -0.13 | -0.84 | |
Free cash flow yield | -5.04 | -0.05 | -0.02 | -0.07 | -0.21 | |
Debt to equity | 0.01 | 1 | 0.98 | 0.24 | 0.45 | |
Debt to assets | 0.01 | 0.52 | 0.38 | 0.18 | 0.25 | |
Net debt to EBITDA | 0.24 | -1.5 | -1.79 | -4.48 | -2.48 | |
Current ratio | 1.93 | 0.42 | 0.28 | 0.71 | 0.09 | |
Interest coverage | -347.63 | -12.79 | -0.77 | -1.06 | -2.05 | |
Income quality | 1.52 | 0.24 | 0.09 | 0.55 | 0.07 | |
Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
Payout ratio | 0 | 0 | 0 | 0 | 0 | |
Sales general and administrative to revenue | 0.29 | 0.83 | 0.68 | 0.45 | 0.78 | |
Research and developement to revenue | 0 | 0 | 0 | 0 | 0 | |
Intangibles to total assets | 0 | 0.2 | 0.43 | 0.66 | 0.63 | |
Capex to operating cash flow | 0.56 | 2.7 | 0.36 | 0.37 | 2.42 | |
Capex to revenue | -0.39 | -1.31 | -0.05 | -0.1 | -0.25 | |
Capex to depreciation | -10.9 | -9.55 | -0.41 | -1.78 | -2.84 | |
Stock based compensation to revenue | 0 | 0.05 | 0.04 | 0.08 | 0.14 | |
Graham number | 2.25 | 0.69 | 0.76 | 2.27 | 2.21 | |
ROIC | -0.27 | -0.31 | -0.33 | -0.08 | -0.14 | |
Return on tangible assets | -0.18 | -0.92 | -1.04 | -0.4 | -0.76 | |
Graham Net | -0.01 | -0.11 | -0.2 | -0.32 | -0.5 | |
Working capital | 834.38K | -4.17M | -7.4M | -4.39M | -37.03M | |
Tangible asset value | 2.62M | 4.38M | -866.26K | 9.38M | -8.03M | |
Net current asset value | 834.38K | -4.17M | -9.76M | -20.11M | -45.27M | |
Invested capital | 0.01 | 1 | 0.98 | 0.24 | 0.45 | |
Average receivables | 465.26K | 683.77K | 394.81K | 900.44K | 1.02M | |
Average payables | 1.21M | 898.53K | 1.53M | 2.87M | 5.09M | |
Average inventory | 3.5K | 90K | 130K | 3.24M | 4.43M | |
Days sales outstanding | 246.96 | 32.33 | 15.85 | 24.1 | 9.84 | |
Days payables outstanding | 258.31 | 153.72 | 149.54 | 102.99 | 162.27 | |
Days of inventory on hand | 0 | 25.7 | 6.05 | 175.08 | 62.27 | |
Receivables turnover | 1.48 | 11.29 | 23.03 | 15.15 | 37.11 | |
Payables turnover | 1.41 | 2.37 | 2.44 | 3.54 | 2.25 | |
Inventory turnover | 0 | 14.2 | 60.32 | 2.08 | 5.86 | |
ROE | -0.25 | -1.43 | -1.53 | -0.19 | -0.5 | |
Capex per share | -0.2 | -0.1 | -0.01 | -0.03 | -0.06 |
Quarterly Fundamentals Overview
Last date of statement is 2023-06-30 for Q3
Metric | History | 2022-06-30 | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-06-30 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 0.05 | 0.04 | 0.05 | 0.06 | 0.05 | |
Net income per share | -0.06 | -0.2 | -0.03 | -0.03 | -0.06 | |
Operating cash flow per share | -0.02 | 0 | -0.01 | 0 | 0 | |
Free cash flow per share | -0.02 | -0.02 | -0.01 | 0 | 0 | |
Cash per share | 0 | 0 | 0 | 0 | 0 | |
Book value per share | 0.82 | 0.67 | 0.61 | 0.57 | 0.53 | |
Tangible book value per share | 0.01 | -0.09 | -0.09 | -0.12 | -0.17 | |
Share holders equity per share | 0.82 | 0.67 | 0.61 | 0.57 | 0.53 | |
Interest debt per share | 0.33 | 0.33 | 0.35 | 0.36 | 0.38 | |
Market cap | 76.93M | 36.65M | 12.39M | 10.11M | 5.27M | |
Enterprise value | 106.75M | 64.41M | 44.96M | 43.88M | 39.38M | |
P/E ratio | -3.51 | -0.5 | -0.95 | -0.74 | -0.22 | |
Price to sales ratio | 15.6 | 9.16 | 2.48 | 1.78 | 1.05 | |
POCF ratio | -32.19 | -153.87 | -9.29 | 33.4 | 35.11 | |
PFCF ratio | -37.1 | -22.25 | -9.24 | 33.24 | 60.38 | |
P/B Ratio | 0.98 | 0.59 | 0.21 | 0.18 | 0.1 | |
PTB ratio | 0.98 | 0.59 | 0.21 | 0.18 | 0.1 | |
EV to sales | 21.65 | 16.1 | 8.99 | 7.75 | 7.84 | |
Enterprise value over EBITDA | -31.88 | -4.16 | -46.91 | -51.41 | -16.67 | |
EV to operating cash flow | -44.67 | -270.4 | -33.69 | 145.02 | 262.31 | |
EV to free cash flow | -51.48 | -39.11 | -33.52 | 144.31 | 451.16 | |
Earnings yield | -0.07 | -0.5 | -0.26 | -0.34 | -1.12 | |
Free cash flow yield | -0.03 | -0.04 | -0.11 | 0.03 | 0.02 | |
Debt to equity | 0.39 | 0.45 | 0.54 | 0.59 | 0.65 | |
Debt to assets | 0.25 | 0.25 | 0.28 | 0.3 | 0.31 | |
Net debt to EBITDA | -8.9 | -1.79 | -33.98 | -39.57 | -14.44 | |
Current ratio | 0.14 | 0.09 | 0.06 | 0.08 | 0.06 | |
Interest coverage | -2.37 | -1.76 | -0.86 | -0.62 | -1 | |
Income quality | 0.44 | 0.01 | 0.41 | -0.09 | -0.03 | |
Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
Payout ratio | 0 | 0 | 0 | 0 | 0 | |
Sales general and administrative to revenue | 0.75 | 1.73 | 0.61 | 0.59 | 0.6 | |
Research and developement to revenue | 0 | 0 | 0 | 0 | 0 | |
Intangibles to total assets | 0.64 | 0.63 | 0.61 | 0.61 | 0.62 | |
Capex to operating cash flow | -0.13 | 5.91 | 0.01 | 0 | -0.42 | |
Capex to revenue | 0.06 | -0.35 | 0 | 0 | -0.01 | |
Capex to depreciation | 0.63 | -2.75 | -0.02 | 0 | -0.15 | |
Stock based compensation to revenue | 0.19 | 0.12 | 0.21 | 0.08 | 0.17 | |
Graham number | 1.02 | 1.73 | 0.67 | 0.66 | 0.85 | |
ROIC | -0.04 | -0.05 | -0.02 | -0.01 | -0.03 | |
Return on tangible assets | -0.13 | -0.45 | -0.07 | -0.08 | -0.14 | |
Graham Net | -0.41 | -0.51 | -0.53 | -0.54 | -0.58 | |
Working capital | -33.78M | -37.03M | -43.73M | -43.45M | -55.47M | |
Tangible asset value | 1.05M | -8.03M | -9.32M | -11.7M | -16.27M | |
Net current asset value | -36.33M | -45.27M | -51.47M | -52.76M | -56.02M | |
Invested capital | 0.39 | 0.45 | 0.54 | 0.59 | 0.65 | |
Average receivables | 884.25K | 588.89K | 594.1K | 598.73K | 781.78K | |
Average payables | 5.67M | 6.12M | 6.4M | 6.65M | 6.89M | |
Average inventory | 4.48M | 3.3M | 2.2M | 2.29M | 2.27M | |
Days sales outstanding | 10.8 | 13.19 | 10.83 | 9.46 | 17.35 | |
Days payables outstanding | 156.75 | 172.24 | 241.01 | 320.24 | 279.87 | |
Days of inventory on hand | 111.26 | 66.09 | 73.2 | 122.2 | 77.54 | |
Receivables turnover | 8.34 | 6.83 | 8.31 | 9.51 | 5.19 | |
Payables turnover | 0.57 | 0.52 | 0.37 | 0.28 | 0.32 | |
Inventory turnover | 0.81 | 1.36 | 1.23 | 0.74 | 1.16 | |
ROE | -0.07 | -0.3 | -0.05 | -0.06 | -0.11 | |
Capex per share | 0 | -0.02 | 0 | 0 | 0 |
INLB Frequently Asked Questions
What is Item 9 Labs Corp. stock symbol ?
Item 9 Labs Corp. is a US stock , located in Phoenix of Az and trading under the symbol INLB
What is Item 9 Labs Corp. stock quote today ?
Item 9 Labs Corp. stock price is $0.00025 today.
Is Item 9 Labs Corp. stock public?
Yes, Item 9 Labs Corp. is a publicly traded company.